Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN AND FAMOTIDINE versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN AND FAMOTIDINE versus MECLOFENAMATE SODIUM.
IBUPROFEN AND FAMOTIDINE vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Ibuprofen: Terminal half-life 2-4 hours (normal renal function); prolonged to 3-6 hours in elderly or hepatic impairment. Famotidine: Terminal half-life 2.5-3.5 hours (normal renal function); extended to >20 hours in severe renal impairment (CrCl <10 mL/min).
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Ibuprofen: Renal excretion of metabolites (90%) and unchanged drug (<10%); biliary/fecal (minor). Famotidine: Renal excretion of unchanged drug (65-70%); metabolites (25-30%); biliary/fecal (minor).
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category D/X
Category C
NSAID
NSAID